| Literature DB >> 21496281 |
Jayasree Sengupta1, Meraj Alam Khan, Berthold Huppertz, Debabrata Ghosh.
Abstract
BACKGROUND: Research on antimicrobial cationic peptides (AMPs) has gained pace toward using their potential to replace conventional antibiotics. These peptides preferentially interact with negatively charged membrane lipids typically seen in bacteria and thereby lead to membrane perturbations and membrane dysfunction. However, one possible disadvantage of AMP drugs is their potential for toxicity, especially to those cells which display externalization of negatively charged moieties to the outer leaflet of the plasma membrane during the process of syncytialization. Human placental villous trophoblast is one such cell type. Indeed, intra-vaginal administration of an antimicrobial cationic peptide Ala8,13,18-magainin II amide (AMA) which is a synthetic analogue of magainin 2 derived from Xenopus frog has been observed to result in inhibition of pregnancy establishment in monkeys. However, only little is known about the cellular behavior of early placental cytotrophoblasts (CTB) in the presence of cationic antimicrobial peptides. It is believed that suitable cell culture approaches using AMA as a representative alpha-helical AMP may yield tangible knowledge in this regard.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21496281 PMCID: PMC3098154 DOI: 10.1186/1477-7827-9-49
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Characteristics of targets and primary antibodies used in the study
| Antigen | Specification of antibody | Final concentration | Purpose* |
|---|---|---|---|
| β-actin | Sheep IgGa | 2.0 μg/ml | Internal normalization control, used in WB |
| Cytokeratin 7 | Mouse IgGb | 6 μg/ml | Epithelial cell marker, used in ICC |
| Cytokeratin 18 neo-epitope (CK18f) | Mouse IgGc | 1:50 (WB); 1:20 (ICC) | Early apoptosis marker, used in WB and ICC |
| βhCG | Rabbit IgGc | 4 μg/ml (WB); 10 μg/ml (ICC) | CTB differentiation marker, used in WB and ICC |
| hPL Goat IgGd | 3 μg/ml (WB); 7 μg/ml (ICC) | CTB differentiation marker, used in WB and ICC | |
| Vimentin | Mouse IgGa | 3 μg/ml | Cytoskeletal protein marker for fibroblasts, used in ICC |
| Vitronectin receptor, Integrin αVβ3 (CD51) | Mouse IgGe | 10 μg/ml | Invasive CTB marker, used in ICC |
| von Willebrand factor | Rabbit IgGc | 25 μg/ml | Endothelial cell marker (in Weibel-Palade bodies), used in ICC |
*see references [17-19,23-27,32] for details.
CTB, cytotrophoblast cells. ICC, immunocytochemistry. WB, Western blot analysis.
aR&D Systems, Minneapolis. bSigma Chemical, St Louis, MO, USA. cDako, Glostrup, Denmark. dSanta Cruz Biotechnology, Santa Cruz, CA, USA. eZymed Laboratories, San Francisco, CA, USA.
Figure 1Immunocytochemical characterization of isolated villous trophoblast cells. Isolated cells were allowed to attach to the collagen biomatrix and immunostained for cytokeratin 7 (CK7; A; green) and βhCG (B; green) and vitronectin receptor (CD51; C; green). Nuclei are counterstained with DAPI (blue). Bar = 40 μm.
Figure 2Representative microphotography of isolated villous trophoblast cells grown on collagen biomatrix. Isolated cells were allowed to attach to the collagen biomatrix and grow for 24 h (A, D), 48 h (B, E) and 96 h (C, F) with 1000 ng/ml AMA (D, E, F) and without AMA (A, B, C) in serum-free culture medium. Bar = 20 μm.
Effect of AMA on time course characteristics of cellular behavior of placental villous CTB in vitro
| Median value (ranges) | |||
|---|---|---|---|
| Time | |||
| Treatment | 24 h | 48 h | 96 h |
| Control | 13.0 (8-18) | 17.5* (11-27) | 23.5(*)(18-32) |
| AMA | 11.0 (9-20) | 13.0 (9-22) | 17.0 (11-24) |
| Control1 | 9.5 (7-12) | 5.5* (9-20) | 21.0(*)(14-30) |
| AMA | 8.0 (6-13) | 11.0 (8-18) | 14.5 (10-21) |
| Control | 2.5 (1-4) | 2.5 (1-5) | 4.5[*](3-8) |
| AMA | 3.5 (2-6) | 3.5 (2-7) | 8.5(*)(5-11) |
| Control | 0 (0-3) | 0 (0-2) | 6[*](3-9) |
| AMA | 3 (0-5) | 3 (1-7) | 11(*)(6-17) |
| Control | 20.5 (11-27) | 22.0 (12-28) | 30.5(*)(19-36) |
| AMA | 18.0 (9-28) | 21.5 (9-24) | 22.5 (11-27) |
| Control | 9.5 (6-12) | 10.0 (7-18) | 16.5(*) |
| AMA | 9.5 (7-13) | 9.5 (6-18) | 11.5 (9-21) |
| Control | 4.0 (2-5) | 4.0 (2-6) | 6.5[*](3-11) |
| AMA | 5.5 (2-7) | 5.5 (2-8) | 9.5(*)(5-16) |
apositive cellular area in per cent. bnumber of positive cells in per cent. cintegrated optical density normalized by that of β-actin per 25 μg of protein.
(*)P < 0.05 compared with any other group; [*]P < 0.05 compared with 24 h and 48 h groups in control treatment; *P < 0.05 compared with control treatment at 96 h.
Figure 3Effect of time and magainin on immunopositive levels of βhCG, hPL and cytokeratin 18 neo-epitope (CK18f). Isolated villous trophoblast cells grown on collagen biomatrix for 24 h (A, D, G, J, M, P), 48 h (B, E, H, K, N, Q) and 96 h (C, F, I, L, O, R) show immunopositive staining for βhCG (A-F; green), hPL (G-L; red), and cytokeratin 18 neo-epitope (CK18f; M-R; green) treated with AMA (D-F, J-L, P-R) and without AMA(A-C, G-I, M-O). The replacement of primary antibody with non-immune mouse IgG (S), non-immune rabbit and goat IgGs (T, U), as well as, pre-neutralization of primary antibodies for βhCG (V) and (hPL) (W) with specific target antigens show no immunopositive staining. Nuclei are counterstained with DAPI (blue). Bars = 20 μm.
Effect of AMA on time course characteristics of levels of βhCG, hPL, and LDH activity in conditioned medium of placental villous CTB in vitro
| Median value (ranges) | |||
|---|---|---|---|
| Time | |||
| Treatment | 24 h | 48 h | 96 h |
| Control | 10.5 (9-14) | 21.0[*] (13-27) | 40.5(*) (26-55) |
| AMA | 8.5 (6-11) | 14.0 (9-19) | 25.5<*> (11-33) |
| Control | 8.5 (7-11) | 13.5[*] (7-17) | 27.0(*) (13-33) |
| AMA | 9.0 (7-11) | 9.5 (6-14) | 15.5<*> (11-24) |
| Control | 15.0 (11-20) | 18.5 (13-26) | 40.5[*] (11-59) |
| AMA | 18.0 (10-23) | 22.0 (16-31) | 64.5(*) (46-87) |
n = 6/each treatment sub-group.
ashown as mIU/ml/105 cells/d. bLDH activity as IU/105 cells/d at 37°C.
(*)P < 0.05 compared with any other group; [*]P < 0.05 compared with other two sub-groups in control treatment group; <*>P < 0.05 compared with other two sub-groups in AMA treatment group.
Figure 4Representative Western blot analysis of immunopositive levels of βhCG, hPL and cytokeratin 18 neo-epitope (CK18f) in cytotrophoblast cells grown in primary culture. Cell lysates of isolated villous trophoblast cells grown on collagen biomatrix for 24 h, 48 h and 96 h with or without AMA (1000 ng/ml) were electrophoretically separated and subjected to immunoblot analysis using β-actin as the internal control.